ifosfamide has been researched along with Ewing Sarcoma in 188 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma." | 9.19 | Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014) |
| "The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma." | 9.14 | Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009) |
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 9.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 9.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 9.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 8.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 8.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 8.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "To assess feasibility and safety of outpatient administration of ifosfamide and etoposide (IE) for pediatric Ewing sarcoma (EWS) patients in a resource-limited setting amid the COVID-19 pandemic." | 8.12 | Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic. ( Saeed, H; Sarfraz, S, 2022) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 7.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)." | 7.75 | Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. ( Bacci, G; Balladelli, A; Berta, M; del Prever, AB; Fagioli, F; Ferrari, S; Palmerini, E; Picci, P; Staals, E; Vanel, D, 2009) |
| "We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide." | 7.74 | [A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008) |
| " The authors describe 2 postpubertal women aged 16 and 25 suffering from Ewing sarcoma who were treated with the very aggressive Sloan-Kettering protocol, which includes high-dose cyclophosphamide and ifosfamide in addition to other drugs." | 7.71 | Successful pregnancy after high-dose cyclophosphamide and ifosfamide treatment in two postpubertal women. ( Kenet, G; Neumann, Y; Rechavi, G; Schachter, J; Sharon, N; Toren, A, 2001) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 7.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 6.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 6.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| "CWS/RMS-96 was an international multicenter trial with randomization between two therapy arms of the standard four-drug therapy (vincristine, ifosfamide, adriamycin, dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) for high-risk rhabdomyosarcoma (RMS), extraskeletal Ewing sarcoma (EES), and undifferentiated sarcoma (UDS) in children, adolescents, and young adults aiming to improve their survival." | 5.51 | Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. ( Alaggio, R; Bisogno, G; Casanova, M; Cecchetto, G; Ferrari, A; Kazanowska, B; Klingebiel, T; Koscielniak, E; Kosztyla, D; Ladenstein, R; Ljungman, G; Milano, GM; Niggli, F; Scarzello, G; Sparber-Sauer, M; Vokuhl, C; Zin, A, 2022) |
| "Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma." | 5.51 | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022) |
| "Ewing sarcoma has recently been reported to be sensitive to poly(ADP)-ribose polymerase (PARP) inhibitors." | 5.42 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. ( Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM, 2015) |
| "Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen." | 5.32 | Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide. ( Kramm, CM; Lawrenz, W; Müller, L; Schmidt, KG; Wessalowski, R, 2004) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 5.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma." | 5.20 | Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. ( Brennan, B; Brichard, B; Craft, A; Dirksen, U; Gaspar, N; Gelderblom, H; Hjorth, L; Judson, I; Juergens, H; Kruseova, J; Kühne, T; Ladenstein, RL; Le Deley, MC; Le Teuff, G; Marec-Berard, P; Paulussen, M; van den Berg, H; Wheatley, K; Whelan, J, 2015) |
| "Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma." | 5.19 | Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014) |
| "Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to localized Ewing sarcoma in North America." | 5.16 | Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. ( Dickman, PS; Dormans, JP; Grier, HE; Healey, JH; Krailo, MD; Marcus, K; Pawel, BR; Sailer, S; Weiss, AR; West, DC; Womer, RB, 2012) |
| "Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy." | 5.15 | Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011) |
| "The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma." | 5.14 | Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009) |
| "In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 5.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
| "Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)." | 5.12 | Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006) |
| "Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis." | 5.11 | Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 5.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 5.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| " In this case report, we treated a 20-year-old male patient with cyclophosphamide, doxorubicin, vincristine, dexamethasone, and methotrexate and cytarabine chemotherapy following a diagnosis of Stage IV Burkitt lymphoma." | 4.89 | Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma. ( Choi, KH; Hyun, JY; Kim, JH; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, JY; Lim, SH, 2013) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 4.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| " The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 4.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 4.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "Interval compression (IC), a regimen of alternating vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide every 2 weeks, improves survival for localized Ewing sarcoma (ES), with uncertain effect on metastatic disease." | 4.31 | Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. ( Ghandour, K; Halalsheh, H; Ibrahimi, AKH; Ismael, T; Sarhan, N; Shehadeh, A; Sultan, I; Zandaki, D, 2023) |
| "To assess feasibility and safety of outpatient administration of ifosfamide and etoposide (IE) for pediatric Ewing sarcoma (EWS) patients in a resource-limited setting amid the COVID-19 pandemic." | 4.12 | Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic. ( Saeed, H; Sarfraz, S, 2022) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 3.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)." | 3.75 | Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. ( Bacci, G; Balladelli, A; Berta, M; del Prever, AB; Fagioli, F; Ferrari, S; Palmerini, E; Picci, P; Staals, E; Vanel, D, 2009) |
| "We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide." | 3.74 | [A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008) |
| " During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus." | 3.72 | Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? ( Bellos, F; Egerer, G; Harter, C; Ho, AD; Kasper, B; Krasniqi, F; Meissner, J, 2004) |
| "Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37." | 3.71 | Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002) |
| " The authors describe 2 postpubertal women aged 16 and 25 suffering from Ewing sarcoma who were treated with the very aggressive Sloan-Kettering protocol, which includes high-dose cyclophosphamide and ifosfamide in addition to other drugs." | 3.71 | Successful pregnancy after high-dose cyclophosphamide and ifosfamide treatment in two postpubertal women. ( Kenet, G; Neumann, Y; Rechavi, G; Schachter, J; Sharon, N; Toren, A, 2001) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 3.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "Patients with cutaneous/subcutaneous Ewing sarcoma may have better prognosis than those with Ewing sarcoma at other anatomical sites." | 3.01 | Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma. ( Aiba, H; Arakawa, A; Imai, T; Iwata, S; Kawai, A; Kimura, H; Kobayashi, E; Kojima, Y; Ogawa, C; Shimoi, T; Sudo, K; Yazaki, S; Yonemori, K; Yoshida, A, 2023) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 2.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 2.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| " A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86." | 2.74 | Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009) |
| "The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients." | 2.73 | Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. ( Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A, 2008) |
| "Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years." | 2.73 | Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. ( Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ, 2007) |
| "Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine." | 2.70 | Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. ( Ahrens, S; Aulitzky, WE; Dunst, J; Fölsch, UR; Göbel, U; Harms, D; Hense, HW; Henze, G; Jürgens, H; Kremens, B; Lehnert, M; Niemeyer, C; Paulussen, M; Reiter, A; Taeger, D; Voûte, PA; Wagner, A; Zoubek, A, 2001) |
| " These results indicate that there is no identifiable pharmacokinetic basis for insistence on either bolus or infusional methods of IFOS administration." | 2.69 | The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. ( Brennan, C; Hartley, JM; Nicholson, PW; Singer, JM; Souhami, RL, 1998) |
| "Two hundred one patients had no metastases." | 2.69 | Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. ( Cotterill, S; Craft, A; Grimer, R; Imeson, J; Lewis, I; Malcolm, A; Souhami, R; Spooner, D, 1998) |
| "The Cooperative Ewing Sarcoma Study (CESS 86), conducted by the German Society of Pediatric Oncology and Hematology (GPOH), was planned on the basis of the results of the preceding CESS 81 study." | 2.69 | Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. ( Ahrens, S; Braun-Munzinger, G; Dunst, J; Göbel, U; Harms, D; Heinecke, A; Hoffmann, C; Jabar, S; Jürgens, H; Paulussen, M; Rübe, C; Treuner, J; Winkelmann, W; Winkler, K, 1999) |
| "The first Scandinavian protocol for Ewing's sarcoma, SSG IV, resulted in a local control rate of 74% and 5-year metastasis-free survival (MFS) of 43%." | 2.69 | Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. ( Akerman, M; Alvegård, TA; Björk, O; Blomqvist, CP; Elomaa, I; Saeter, G; Stenwig, E; Wiebe, T, 2000) |
| "Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge." | 2.68 | Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. ( Aledo, A; Boland, P; Casper, ES; Gerald, WL; Healey, JH; Heller, G; Kushner, BH; La Quaglia, MP; Meyers, PA; Wollner, N, 1995) |
| "The Cooperative Ewing's Sarcoma Studies, CESS 81 and CESS 86, are multiinstitutional trials with more than 80 participating institutions from Germany, the Netherlands, Austria, and Switzerland." | 2.67 | Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. ( Burgers, JM; Dunst, J; Hawliczek, R; Jürgens, H; Kürten, R; Müschenich, M; Salzer-Kuntschik, M; Sauer, R; Winkelmann, W, 1991) |
| "Extraosseous Ewing sarcoma is a rare, poorly differentiated round-cell tumour that is part of the Ewing sarcoma family of tumours." | 2.61 | Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature. ( Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A, 2019) |
| "The occurrence of primary extraskeletal Ewing's sarcoma (EES) of the spinal epidural space has been rarely reported in the literature." | 2.47 | Extraskeletal Ewing's sarcoma of the thoracic epidural space: case report and review of the literature. ( Bridge, JA; Hori, T; Huang, D; Kanamori, M; Kimura, T; Suzuki, K; Yasuda, T, 2011) |
| "A 17-year-old woman with Ewing sarcoma was treated with a combination of doxorubicin (Adriamycin) and ifosfamide during the 25th to 30th week of gestation, and the baby was delivered at the 32nd week." | 2.42 | Good outcome for infant of mother treated with chemotherapy for ewing sarcoma at 25 to 30 weeks' gestation. ( Hirayama, M; Ishida, A; Nakajima, W; Ogawa, M; Okada, K; Takahashi, M; Takahashi, S; Washino, N, 2004) |
| "Extraskeletal Ewing's sarcoma (EES) is rare and has not been previously described about the cervical spine." | 2.41 | Extraskeletal Ewing's sarcoma: a case report and review of the literature. ( Caulfield, R; Eustace, S; Fennelly, DJ; Hurson, B; Kennedy, JG; O'Rourke, KS, 2000) |
| "Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1." | 1.91 | Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease. ( Bailey, KM; Daley, J; Friehling, E; Halligan, K; Howrie, D; Salgado, CM; Superdock, A, 2023) |
| "Ewing sarcoma is one of the most frequent soft-tissue tumors in pediatric patients." | 1.72 | Analysis of stem cell collections in adult patients with Ewing sarcoma. ( Bach, E; Brückner, M; Franke, GN; Heyn, S; Jentzsch, M; Leiblein, S; Niederwieser, D; Pfannes, R; Platzbecker, U; Pönisch, W; Remane, Y; Rieprecht, S; Schwind, S; Vucinic, V, 2022) |
| "Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | 1.72 | Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Adult Ewing sarcoma (ES) is a rare disease, the optimal treatment model is unknown." | 1.51 | Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. ( He, A; Hu, H; Huang, Y; Shen, Z; Sun, Y; Yao, Y; Zhang, J; Zhou, Y, 2019) |
| "Our study showed that the outpatient administration of interval-compressed regimen is safe and associated with acceptable adherence to this regimen." | 1.51 | Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma. ( Alnassan, A; Elshahoubi, A; Sultan, I, 2019) |
| "In patients with Ewing sarcoma and some distinct subgroups of soft tissue sarcoma (STS), a quantitatively sufficient autologous peripheral blood stem cell (PBSC) collection for stem cell support might facilitate treatment continuation, dose-intensification, and high-dose chemotherapy." | 1.46 | Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients. ( Bruckner, T; Cremer, M; Egerer, G; Heilig, C; Kriegsmann, K; Kriegsmann, M; Müller-Tidow, C; Novotny, P; Wuchter, P, 2017) |
| "The incidence of Ewing sarcoma is lower in non-Caucasian populations, compared with Caucasian populations, for unknown reasons." | 1.43 | Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. ( Aoki, Y; Araki, N; Hamada, K; Imura, Y; Joyama, S; Kakunaga, S; Naka, N; Obata, H; Takenaka, S; Ueda, T; Yoshikawa, H, 2016) |
| "Ewing sarcoma is the second most common bone tumor, occurring mainly in children and young adults." | 1.43 | Maturation toward neuronal tissue in a Ewing sarcoma of bone after chemotherapy. ( Brons, P; Flucke, U; Salet, MC; Schreuder, B; Vogels, R, 2016) |
| "Data on patients with localized Ewing sarcoma family of tumors (ESFT) who have received a uniform chemotherapy protocol are minimal." | 1.42 | Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol. ( Agarwala, S; Bakhshi, S; Biswas, B; Deo, SV; Khan, SA; Mohanti, BK; Rastogi, S; Sharma, MC; Shukla, NK; Vishnubhatla, S, 2015) |
| "Ewing sarcoma has recently been reported to be sensitive to poly(ADP)-ribose polymerase (PARP) inhibitors." | 1.42 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. ( Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM, 2015) |
| "Extraskeletal Ewing's sarcoma is a rare malignant soft tissue tumor, classified within the Ewing's Sarcoma Family Tumors." | 1.39 | Extraskeletal Ewing's Sarcoma: insight into a ten years follow-up. ( Angelici, A; Brunotti, G; Manfredelli, S; Marcantonio, M; Pontone, S; Zitelli, A, 2013) |
| "A 9-year-old girl with Ewing sarcoma had one ovary excised and cryopreserved prior to chemo- and radiotherapy." | 1.39 | Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. ( Andersen, CY; Birkebæk, NH; Clausen, N; Ernst, E; Kjærsgaard, M, 2013) |
| "Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed." | 1.38 | Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome. ( Colpan Oksuz, D; Dervisoglu, S; Hiz, M; Kantarci, F; Koca, S; Molinas Mandel, N; Oner Dincbas, F; Selcukbiricik, F; Tural, D; Turna, H, 2012) |
| "Mice implanted with Ewing's sarcoma tumours received the following treatments: saline, ifosfamide, ifosfamide + NAC concurrently, pre-treatment with NAC + ifosfamide, or NAC alone." | 1.38 | The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. ( Figueredo, R; Hanly, L; Koren, G; Koropatnick, J; Rieder, MJ, 2012) |
| "We evaluated whether Korean Ewing sarcoma family of tumors patients have poorer outcomes than Euro-American patients." | 1.37 | Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. ( Cho, J; Cho, WH; Jeon, DG; Kim, DH; Kim, MS; Koh, JS; Kong, CB; Lee, JA; Lee, SY; Lim, JS; Song, WS; Yoo, JY, 2011) |
| "We report a case of primary cutaneous Ewing's sarcoma in a 21-year-old woman." | 1.37 | [Primitive cutaneous Ewing's sarcoma: a diagnostic and therapeutic dilemma]. ( Delaplace, M; Goré, C; Machet, L; Mélard, P; Perrinaud, A; Vergier, B, 2011) |
| "A primitive neuroectodermal tumor (PNET) is a small round cell tumor that arises from the nerve crest." | 1.36 | Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin. ( Horiuchi, K; Kondo, Y; Mizutani, S; Ohgaki, K; Sato, M, 2010) |
| "The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare." | 1.36 | Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. ( Andreoiu, M; Beck, SDW; Brames, MJ; Cheng, L; Ehrlich, Y; Einhorn, LH; Foster, RS; Ulbright, TM, 2010) |
| "Extraskeletal Ewing's sarcoma (EES) is a rare form of soft tissue sarcoma." | 1.36 | Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. ( Ajarim, D; Al Dayel, F; Allam, A; Bazarbashi, S; El Weshi, A; Memon, M; Pant, R, 2010) |
| "The outcome of Ewing's sarcoma depends on the anatomical site of the tumor." | 1.35 | Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. ( Arpaci, F; Ataergin, S; Beyzadeoglu, M; Komurcu, S; Oysul, K; Ozet, A; Ozturk, M; Solchaga, L; Surenkok, S; Turan, M, 2009) |
| "After a search for Ewing tumors in the database of a single institution over a period of 20 years, 16 out of 192 cases were found to have extra-osseous primary tumors." | 1.35 | Extra-osseous Ewing sarcoma. ( Heinen, RC; Merks, JH; van den Berg, H; van der Pal, HJ, 2009) |
| "Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies." | 1.35 | Prognostic factors for local and distant control in Ewing sarcoma family of tumors. ( Billups, CA; Krasin, MJ; Liu, T; Navid, F; Rao, BN; Rodríguez-Galindo, C, 2008) |
| "Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution." | 1.34 | Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. ( Mai, WY; Nguyen, TX; Paulino, AC; Teh, BS; Wen, BC, 2007) |
| "From 1979 to 2002, 27 patients with Ewing's sarcoma (20) or PNET (7) were treated." | 1.34 | Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands. ( Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M, 2007) |
| "The local management of Ewing sarcoma family of tumors (ESFT) often centers on the surgical resectability of the primary lesion and physician biases regarding differences in the morbidity between primary surgical and radiotherapeutic management." | 1.33 | Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. ( Billups, CA; Davidoff, AM; Fuller, CE; Krasin, MJ; Merchant, TE; Neel, MD; Rodriguez-Galindo, C, 2005) |
| " Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed." | 1.33 | Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. ( Craft, A; Juergens, C; Juergens, H; Lewis, I; Michon, J; Oberlin, O; Paulussen, M; Weston, C; Whelan, J; Zoubek, A, 2006) |
| "Etoposide dose was reduced, or omitted, in 24% of cycles." | 1.32 | Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. ( Briggs, T; Cannon, S; Cassoni, AM; Cobb, J; Driver, D; Hall-Craggs, M; Kilby, A; McTiernan, A; Michelagnoli, M; Pringle, J; Sandison, A; Strauss, SJ; Whelan, JS; Witt, J, 2003) |
| "An ileoilealic intussusception was found, caused by a small bowel tumour, which almost completely obstructed the intestinal lumen." | 1.32 | Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report. ( Boehm, R; Joppich, I; Landes, J; Schmid, I; Till, H, 2003) |
| "Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen." | 1.32 | Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide. ( Kramm, CM; Lawrenz, W; Müller, L; Schmidt, KG; Wessalowski, R, 2004) |
| "Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs." | 1.32 | Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax. ( Alper, F; Eroğlu, A; Gündoğdu, C; Karaoğlanoğlu, N; Kürkçüoğlu, IC, 2004) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 1.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "Older age and axial location of Ewing's sarcoma have been reported as unfavorable prognostic factors." | 1.32 | Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. ( Argon, A; Basaran, M; Bavbek, SE; Camlica, H; Darendeliler, E; Dizdar, Y; Onat, H; Ozger, H; Sakar, B; Yaman, F, 2004) |
| "Ewing sarcoma is the second most common bone tumor in childhood." | 1.32 | Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide. ( Sancéau, J; Wietzerbin, J, 2004) |
| "Although the overall results of treatment of Ewing's tumors have improved, patients with high-risk factors, including metastatic disease at diagnosis, bulky primary tumors, axial sites, and age >15 years, continue to have poor prognoses." | 1.31 | High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors. ( Iwamoto, Y; Matsuda, S; Matsunobu, T; Sakamoto, A; Tanaka, K, 2002) |
| "Ewing sarcoma is the second most common bone tumor in childhood." | 1.31 | Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. ( Delattre, O; Poupon, MF; Sancéau, J; Sastre-Garau, X; Wietzerbin, J, 2002) |
| "Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered." | 1.31 | Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. ( Bacchini, P; Bacci, G; Bertoni, F; Donati, D; Ferrari, S; Forni, C; Longhi, A; Manfrini, M; Picci, P; Rimondini, S, 2000) |
| "Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours." | 1.31 | Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000) |
| "Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone." | 1.31 | Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. ( Ahrens, S; Amann, G; Dockhorn-Dworniczak, B; Dunst, J; Exner, GU; Gadner, H; Göbel, U; Harms, D; Janka-Schaub, G; Jürgens, H; Kornhuber, B; Kotz, R; Müller-Weihrich, S; Paulussen, M; Treuner, J; Voûte, PA; Welte, K; Winkelmann, W; Zoubek, A, 2001) |
| "We describe a 16-year-old girl with a Ewing sarcoma who was given post-operative treatment with HDI (15 mg/m(2) infused over 5 days)." | 1.31 | Painful peripheral neuropathy after treatment with high-dose ifosfamide. ( Frisk, P; Stålberg, E; Strömberg, B, 2001) |
| "Since 1985, 54 with localized Ewing's sarcoma of bone were treated at the Onco-Orthopedics Clinic of the Sofia University Hospital (Sofia, Bulgaria)." | 1.31 | [Treatment of Ewing's sarcoma with 2 different protocols]. ( Mihova, A; Mumdjiev, I; Sokolov, T; Stoianova, A, 2001) |
| "Records of 34 patients with ES/PNET who received the IVAD chemotherapy regimens were reviewed." | 1.30 | The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. ( Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E, 1997) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| "Extraskeletal Ewing's sarcoma is rare, and very few data are available addressing optimal surgical and oncologic treatment modalities." | 1.30 | Extraskeletal Ewing's sarcoma. ( Ahmad, R; Davis, M; Mayol, BR; Rougraff, BT, 1999) |
| "Ifosfamide is an alkylating agent which has been incorporated into frontline therapy for a number of malignant paediatric tumours." | 1.29 | Ifosfamide nephrotoxicity in paediatric cancer patients. ( Ashraf, MS; Brady, J; Breatnach, F; Deasy, PF; O'Meara, A, 1994) |
| " Moreover, a dose-response relationship was detectable: 1/6 patients without lung irradiation vs." | 1.29 | Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. ( Dunst, J; Jürgens, H; Paulussen, M, 1993) |
| "Seventeen patients with Ewing's sarcoma were divided into 3 groups according to treatment." | 1.29 | Ewing's sarcoma: evaluation of chemotherapy in 17 cases. ( Hamada, M; Inoue, H; Nakagawa, Y; Ozaki, T; Sugihara, S; Taguchi, K, 1993) |
| "Ifosfamide is a derivative of cyclophosphamide and is used to treat malignant tumours." | 1.29 | Hypophosphataemic rickets after ifosfamide treatment in children. ( Sweeney, LE, 1993) |
| "Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation." | 1.28 | Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992) |
| "Two cases of Ewing's sarcoma originating from the adult rib were reported." | 1.28 | [Two cases of Ewing's sarcoma originating from the adult rib]. ( Akiba, Y; Fujita, Y; Ikushima, Y; Ishida, S; Ohosaki, Y; Onodera, S; Sakai, E; Saotome, K; Shimizu, T; Tagaki, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (2.66) | 18.7374 |
| 1990's | 45 (23.94) | 18.2507 |
| 2000's | 64 (34.04) | 29.6817 |
| 2010's | 55 (29.26) | 24.3611 |
| 2020's | 19 (10.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sarfraz, S | 1 |
| Saeed, H | 1 |
| Sparber-Sauer, M | 2 |
| Ferrari, A | 2 |
| Kosztyla, D | 1 |
| Ladenstein, R | 5 |
| Cecchetto, G | 1 |
| Kazanowska, B | 2 |
| Scarzello, G | 1 |
| Ljungman, G | 2 |
| Milano, GM | 2 |
| Niggli, F | 2 |
| Alaggio, R | 1 |
| Vokuhl, C | 2 |
| Casanova, M | 1 |
| Klingebiel, T | 3 |
| Zin, A | 1 |
| Koscielniak, E | 3 |
| Bisogno, G | 3 |
| Zandaki, D | 1 |
| Ismael, T | 1 |
| Halalsheh, H | 2 |
| Ibrahimi, AKH | 1 |
| Sarhan, N | 1 |
| Ghandour, K | 1 |
| Shehadeh, A | 2 |
| Sultan, I | 3 |
| Laskar, S | 2 |
| Sinha, S | 1 |
| Chatterjee, A | 1 |
| Khanna, N | 2 |
| Manjali, JJ | 1 |
| Puri, A | 1 |
| Gulia, A | 1 |
| Nayak, P | 1 |
| Vora, T | 1 |
| Chinnaswamy, G | 2 |
| Prasad, M | 1 |
| Bajpai, J | 2 |
| Juvekar, S | 1 |
| Desai, S | 1 |
| Janu, A | 1 |
| Rangarajan, V | 1 |
| Purandare, N | 1 |
| Shah, S | 1 |
| Rekhi, B | 2 |
| Jambhekar, N | 1 |
| Muckaden, MA | 1 |
| Kurkure, P | 1 |
| Franke, GN | 1 |
| Pfannes, R | 1 |
| Heyn, S | 1 |
| Brückner, M | 1 |
| Rieprecht, S | 1 |
| Bach, E | 1 |
| Remane, Y | 1 |
| Leiblein, S | 1 |
| Pönisch, W | 1 |
| Niederwieser, D | 1 |
| Schwind, S | 1 |
| Platzbecker, U | 1 |
| Jentzsch, M | 1 |
| Vucinic, V | 1 |
| Lucari, B | 1 |
| Tallis, E | 1 |
| Sutton, VR | 1 |
| Porea, T | 1 |
| Corvest, V | 1 |
| Marec-Bérard, P | 6 |
| Lervat, C | 1 |
| Pacquement, H | 1 |
| Toulmonde, M | 1 |
| Gentet, JC | 4 |
| Laurence, V | 5 |
| Cleirec, M | 1 |
| Mansuy, L | 1 |
| Bompas, E | 1 |
| Castex, MP | 1 |
| Taque, S | 1 |
| Filhon, B | 1 |
| Tabone, MD | 1 |
| Verité, C | 1 |
| Entz-Werle, N | 1 |
| Saumet, L | 1 |
| Guimard, G | 1 |
| Pondrom, M | 1 |
| Chevreau, C | 1 |
| Flandrin, J | 1 |
| Duranteau, L | 1 |
| Rousset-Jablonski, C | 1 |
| Brugières, L | 1 |
| Jimenez, M | 1 |
| Le Deley, MC | 4 |
| Gaspar, N | 6 |
| Fresneau, B | 1 |
| Liu, YC | 3 |
| Yeh, TC | 3 |
| Wu, PS | 3 |
| Sheu, JC | 3 |
| Lee, HC | 3 |
| Yeung, CY | 3 |
| Jiang, CB | 3 |
| Liu, HC | 3 |
| Hou, JY | 3 |
| Chan, WT | 3 |
| Brennan, B | 5 |
| Kirton, L | 2 |
| Martín-Broto, J | 3 |
| Sastre, A | 3 |
| Gelderblom, H | 4 |
| Owens, C | 3 |
| Fenwick, N | 3 |
| Strauss, S | 3 |
| Moroz, V | 3 |
| Whelan, J | 9 |
| Wheatley, K | 5 |
| Daley, J | 1 |
| Halligan, K | 1 |
| Howrie, D | 1 |
| Salgado, CM | 1 |
| Superdock, A | 1 |
| Friehling, E | 1 |
| Bailey, KM | 1 |
| Aiba, H | 1 |
| Kojima, Y | 1 |
| Shimoi, T | 1 |
| Sudo, K | 1 |
| Yazaki, S | 1 |
| Imai, T | 1 |
| Yoshida, A | 1 |
| Iwata, S | 2 |
| Kobayashi, E | 1 |
| Kawai, A | 2 |
| Arakawa, A | 1 |
| Ogawa, C | 2 |
| Kimura, H | 1 |
| Yonemori, K | 1 |
| Cash, T | 1 |
| Krailo, MD | 7 |
| Buxton, AB | 1 |
| Pawel, BR | 2 |
| Healey, JH | 5 |
| Binitie, O | 1 |
| Marcus, KJ | 2 |
| Grier, HE | 10 |
| Grohar, PJ | 1 |
| Reed, DR | 1 |
| Weiss, AR | 2 |
| Gorlick, R | 3 |
| Janeway, KA | 2 |
| DuBois, SG | 4 |
| Womer, RB | 6 |
| Salah, S | 1 |
| Abuhijla, F | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Abdelal, S | 1 |
| Almousa, A | 1 |
| Jaber, O | 1 |
| Abu-Hijlih, R | 1 |
| Maroun, CA | 1 |
| Khalifeh, I | 1 |
| Tfayli, A | 1 |
| Moukarbel, RV | 1 |
| Zhang, J | 1 |
| Huang, Y | 1 |
| Sun, Y | 1 |
| He, A | 1 |
| Zhou, Y | 1 |
| Hu, H | 1 |
| Yao, Y | 1 |
| Shen, Z | 1 |
| Anderton, J | 1 |
| Kaiser, S | 1 |
| Fernández-Pinto, M | 1 |
| Evans, A | 1 |
| Totadri, S | 1 |
| Bansal, D | 1 |
| Rao, KLN | 1 |
| Jain, R | 1 |
| Saxena, AK | 1 |
| Kapoor, R | 1 |
| Samujh, R | 1 |
| Trehan, A | 1 |
| Imai, K | 1 |
| Yamasaki, T | 1 |
| Sakamoto, H | 1 |
| Nakamura, K | 1 |
| Mizowaki, T | 1 |
| Ogawa, O | 1 |
| Aoyama, T | 1 |
| Howe, AS | 1 |
| Pearce, J | 1 |
| Lian, F | 1 |
| Ribbons, L | 1 |
| Chumbalkar, V | 1 |
| Nazeer, T | 1 |
| Kogan, BA | 1 |
| Panda, GS | 1 |
| Chandrasekharan, A | 1 |
| Bhargava, P | 1 |
| Srinivas, S | 1 |
| Dandekar, S | 1 |
| Mokal, S | 1 |
| Menon, N | 1 |
| Patil, V | 1 |
| Noronha, V | 1 |
| Joshi, A | 1 |
| Prabhash, K | 1 |
| Banavali, SD | 1 |
| Gupta, S | 1 |
| Scheer, M | 1 |
| Paulussen, M | 14 |
| Bielack, SS | 2 |
| Seitz, G | 1 |
| Fuchs, J | 1 |
| Hallmen, E | 1 |
| Wagner, MJ | 1 |
| Gopalakrishnan, V | 1 |
| Ravi, V | 1 |
| Livingston, JA | 1 |
| Conley, AP | 1 |
| Araujo, D | 1 |
| Somaiah, N | 1 |
| Zarzour, MA | 1 |
| Ratan, R | 1 |
| Wang, WL | 1 |
| Patel, SR | 2 |
| Lazar, A | 1 |
| Ludwig, JA | 1 |
| Benjamin, RS | 2 |
| Kriegsmann, K | 1 |
| Heilig, C | 1 |
| Cremer, M | 1 |
| Novotny, P | 1 |
| Kriegsmann, M | 1 |
| Bruckner, T | 1 |
| Müller-Tidow, C | 1 |
| Egerer, G | 2 |
| Wuchter, P | 1 |
| Ahmed, SK | 1 |
| Randall, RL | 1 |
| Harmsen, WS | 1 |
| Krailo, M | 4 |
| Geller, DS | 1 |
| Sorger, JI | 1 |
| Granowetter, L | 3 |
| Gorlick, RG | 1 |
| Laack, NNI | 1 |
| Jamshidi, K | 1 |
| Ramezan Shirazi, M | 1 |
| Bagherifard, A | 1 |
| Mirzaei, A | 1 |
| Elshahoubi, A | 1 |
| Alnassan, A | 1 |
| Lim, SH | 1 |
| Lee, JY | 2 |
| Kim, JH | 1 |
| Choi, KH | 1 |
| Hyun, JY | 1 |
| Ko, YH | 1 |
| Lee, J | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Yamaoka, M | 1 |
| Akiyama, M | 1 |
| Yokokawa, Y | 1 |
| Terao, Y | 1 |
| Yokoi, K | 1 |
| Kato, T | 1 |
| Fukushima, T | 1 |
| Sakurai, H | 1 |
| Ida, H | 1 |
| Clement, J | 1 |
| Varlotto, J | 1 |
| Rybka, W | 1 |
| Frauenhoffer, E | 1 |
| Drabick, JJ | 1 |
| Lionel, AP | 1 |
| John, RR | 1 |
| Mathai, S | 1 |
| Paioli, A | 1 |
| Luksch, R | 3 |
| Fagioli, F | 4 |
| Tamburini, A | 3 |
| Cesari, M | 3 |
| Palmerini, E | 3 |
| Abate, ME | 2 |
| Marchesi, E | 1 |
| Balladelli, A | 3 |
| Pratelli, L | 1 |
| Ferrari, S | 11 |
| Zitelli, A | 1 |
| Manfredelli, S | 1 |
| Brunotti, G | 1 |
| Marcantonio, M | 1 |
| Pontone, S | 1 |
| Angelici, A | 1 |
| Lewis, I | 6 |
| Ranft, A | 2 |
| Le Teuff, G | 2 |
| Michon, J | 3 |
| van den Berg, H | 6 |
| Hjorth, L | 3 |
| Judson, I | 2 |
| Juergens, H | 4 |
| Craft, A | 5 |
| Oberlin, O | 7 |
| Dirksen, U | 4 |
| Raciborska, A | 1 |
| Bilska, K | 1 |
| Drabko, K | 1 |
| Chaber, R | 1 |
| Sobol, G | 1 |
| Pogorzała, M | 1 |
| Wyrobek, E | 1 |
| Połczyńska, K | 1 |
| Rogowska, E | 1 |
| Rodriguez-Galindo, C | 5 |
| Wożniak, W | 1 |
| Biswas, B | 1 |
| Rastogi, S | 1 |
| Khan, SA | 1 |
| Shukla, NK | 1 |
| Deo, SV | 1 |
| Agarwala, S | 1 |
| Mohanti, BK | 1 |
| Sharma, MC | 1 |
| Vishnubhatla, S | 1 |
| Bakhshi, S | 1 |
| Magnan, H | 1 |
| Goodbody, CM | 1 |
| Riedel, E | 1 |
| Pratilas, CA | 1 |
| Wexler, LH | 3 |
| Chou, AJ | 1 |
| Ando, M | 1 |
| Brunetto, AL | 1 |
| Castillo, LA | 1 |
| Petrilli, AS | 1 |
| Macedo, CD | 1 |
| Boldrini, E | 1 |
| Costa, C | 1 |
| Almeida, MT | 1 |
| Kirst, D | 1 |
| Pereira, WV | 1 |
| Watanabe, FM | 1 |
| Pizza, M | 1 |
| Benites, E | 1 |
| Morais, V | 1 |
| Gadelha, A | 1 |
| Nakasato, A | 1 |
| Abujamra, AL | 1 |
| Gregianin, LJ | 1 |
| Loschi, S | 1 |
| Dufour, C | 1 |
| Goma, G | 1 |
| Valteau-Couanet, D | 1 |
| Karski, EE | 1 |
| McIlvaine, E | 1 |
| Segal, MR | 1 |
| Meyers, PA | 8 |
| Felgenhauer, J | 3 |
| Marina, N | 5 |
| Ladenstein, RL | 1 |
| Kruseova, J | 1 |
| Kühne, T | 1 |
| Brichard, B | 1 |
| Engert, F | 1 |
| Schneider, C | 1 |
| Weiβ, LM | 1 |
| Probst, M | 1 |
| Fulda, S | 1 |
| Mascarenhas, L | 1 |
| Felgenhauer, JL | 2 |
| Bond, MC | 1 |
| Villaluna, D | 1 |
| Femino, JD | 1 |
| Laack, NN | 1 |
| Ranganathan, S | 2 |
| Meyer, J | 2 |
| Ben-Ami, T | 1 |
| Waldman, E | 1 |
| Marc, W | 1 |
| Weintraub, M | 1 |
| Revel-Vilk, S | 1 |
| Fried, I | 1 |
| Yonemoto, T | 2 |
| Takahashi, M | 2 |
| Maru, M | 1 |
| Tomioka, A | 1 |
| Saito, M | 1 |
| Araki, Y | 1 |
| Tazaki, M | 1 |
| Tsuchiya, M | 1 |
| Kamoda, H | 1 |
| Ishii, T | 4 |
| Takenaka, S | 1 |
| Naka, N | 1 |
| Obata, H | 2 |
| Joyama, S | 1 |
| Hamada, K | 1 |
| Imura, Y | 1 |
| Kakunaga, S | 1 |
| Aoki, Y | 1 |
| Ueda, T | 2 |
| Araki, N | 1 |
| Yoshikawa, H | 1 |
| Yoshihara, H | 1 |
| Kamiya, T | 1 |
| Hosoya, Y | 1 |
| Hasegawa, D | 1 |
| Asanuma, H | 1 |
| Mizuno, R | 1 |
| Hosoya, R | 1 |
| Manabe, A | 1 |
| Salet, MC | 1 |
| Vogels, R | 1 |
| Brons, P | 1 |
| Schreuder, B | 1 |
| Flucke, U | 1 |
| Yodoya, N | 1 |
| Iwamoto, S | 1 |
| Matsumine, A | 2 |
| Azuma, E | 1 |
| Toyoda, H | 1 |
| Miura, Y | 1 |
| Nakatani, K | 1 |
| Imai, H | 1 |
| Hirayama, M | 2 |
| Komada, Y | 1 |
| Zhang, T | 1 |
| Zhang, S | 1 |
| Yang, F | 1 |
| Wang, L | 1 |
| Zhu, S | 1 |
| Qiu, B | 1 |
| Li, S | 1 |
| Deng, Z | 1 |
| Gilman, AL | 1 |
| Oesterheld, J | 1 |
| Craft, AW | 2 |
| Hackshaw, A | 1 |
| Douglas, C | 1 |
| Dunst, J | 10 |
| Schuck, A | 3 |
| Winkelmann, W | 6 |
| Köhler, G | 1 |
| Poremba, C | 1 |
| Zoubek, A | 5 |
| Hunold, A | 1 |
| Cassoni, A | 1 |
| Spooner, D | 3 |
| Grimer, R | 3 |
| McTiernan, A | 2 |
| Jürgens, H | 13 |
| Ataergin, S | 1 |
| Ozet, A | 1 |
| Solchaga, L | 1 |
| Turan, M | 1 |
| Beyzadeoglu, M | 1 |
| Oysul, K | 1 |
| Arpaci, F | 1 |
| Komurcu, S | 1 |
| Surenkok, S | 1 |
| Ozturk, M | 1 |
| del Prever, AB | 1 |
| Staals, E | 1 |
| Berta, M | 1 |
| Picci, P | 7 |
| Bacci, G | 10 |
| Vanel, D | 1 |
| Dantonello, TM | 1 |
| Int-Veen, C | 1 |
| Harms, D | 5 |
| Leuschner, I | 1 |
| Schmidt, BF | 1 |
| Herbst, M | 1 |
| Scheel-Walter, HG | 1 |
| Dickerhoff, R | 1 |
| Kirsch, S | 1 |
| Brecht, I | 1 |
| Schmelzle, R | 1 |
| Greulich, M | 1 |
| Gadner, H | 2 |
| Greiner, J | 1 |
| Marky, I | 1 |
| Treuner, J | 4 |
| Womer, R | 1 |
| Devidas, M | 1 |
| Wang, C | 1 |
| Bernstein, M | 2 |
| Leavey, P | 1 |
| Gebhardt, M | 1 |
| Healey, J | 1 |
| Shamberger, RC | 1 |
| Goorin, A | 1 |
| Miser, J | 1 |
| Arndt, CA | 1 |
| Sailer, S | 2 |
| Marcus, K | 2 |
| Perlman, E | 1 |
| Dickman, P | 1 |
| Heinen, RC | 1 |
| van der Pal, HJ | 1 |
| Merks, JH | 1 |
| Briccoli, A | 1 |
| Rocca, M | 1 |
| Salone, M | 1 |
| Ferrari, C | 1 |
| Di Fiore, M | 1 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Peeters, J | 1 |
| Meitert, J | 1 |
| Paulides, M | 1 |
| Beck, JD | 1 |
| Langer, T | 1 |
| Bölling, T | 1 |
| Ernst, I | 1 |
| Willich, N | 3 |
| Vincentelli, F | 1 |
| Caruso, G | 1 |
| Figarella-Branger, D | 1 |
| Fawaz, O | 1 |
| Rey, A | 1 |
| Niaudet, P | 1 |
| Ridola, V | 1 |
| Orbach, D | 1 |
| Bergeron, C | 1 |
| Defachelles, AS | 1 |
| Schmitt, C | 2 |
| Rubie, H | 1 |
| Munzer, M | 1 |
| Plantaz, D | 1 |
| Deville, A | 1 |
| Minard, V | 1 |
| Corradini, N | 2 |
| Leverger, G | 1 |
| de Vathaire, F | 1 |
| Casado-Zapico, S | 1 |
| Rodriguez-Blanco, J | 1 |
| García-Santos, G | 1 |
| Martín, V | 1 |
| Sánchez-Sánchez, AM | 1 |
| Antolín, I | 1 |
| Rodriguez, C | 1 |
| Cai, JY | 1 |
| Tang, JY | 1 |
| Pan, C | 1 |
| Xu, M | 1 |
| Xue, HL | 1 |
| Zhou, M | 1 |
| Dong, L | 1 |
| Ye, QD | 1 |
| Jiang, H | 1 |
| Shen, SH | 1 |
| Chen, J | 1 |
| Ohgaki, K | 1 |
| Horiuchi, K | 1 |
| Mizutani, S | 1 |
| Sato, M | 1 |
| Kondo, Y | 1 |
| Ehrlich, Y | 1 |
| Beck, SDW | 1 |
| Ulbright, TM | 1 |
| Cheng, L | 1 |
| Brames, MJ | 1 |
| Andreoiu, M | 1 |
| Foster, RS | 1 |
| Einhorn, LH | 1 |
| El Weshi, A | 2 |
| Allam, A | 2 |
| Ajarim, D | 1 |
| Al Dayel, F | 1 |
| Pant, R | 1 |
| Bazarbashi, S | 2 |
| Memon, M | 2 |
| Pötschger, U | 1 |
| Indelicato, DJ | 1 |
| Keole, SR | 1 |
| Lagmay, JP | 1 |
| Morris, CG | 1 |
| Gibbs, CP | 1 |
| Scarborough, MT | 1 |
| Islam, S | 1 |
| Marcus, RB | 1 |
| Odri, GA | 1 |
| Dumoucel, S | 1 |
| Picarda, G | 1 |
| Battaglia, S | 1 |
| Lamoureux, F | 1 |
| Rousseau, J | 1 |
| Tirode, F | 1 |
| Laud, K | 1 |
| Delattre, O | 2 |
| Gouin, F | 1 |
| Heymann, D | 1 |
| Redini, F | 1 |
| Sundby Hall, K | 1 |
| Tienghi, A | 3 |
| Wiebe, T | 2 |
| Alvegard, TA | 2 |
| Brach Del Prever, A | 4 |
| Alberghini, M | 1 |
| Gandola, L | 2 |
| Mercuri, M | 7 |
| Capanna, R | 1 |
| Mapelli, S | 1 |
| Prete, A | 2 |
| Carli, M | 2 |
| Barbieri, E | 8 |
| Smeland, S | 2 |
| Mora, J | 1 |
| de Torres, C | 1 |
| Parareda, A | 1 |
| Torner, F | 1 |
| Galván, P | 1 |
| Rodríguez, E | 1 |
| Cardesa, T | 1 |
| Salvador, H | 1 |
| Suñol, M | 1 |
| Huguet, R | 1 |
| Cruz, O | 1 |
| Lee, JA | 1 |
| Kim, DH | 1 |
| Cho, J | 1 |
| Lim, JS | 1 |
| Koh, JS | 1 |
| Yoo, JY | 1 |
| Kim, MS | 1 |
| Kong, CB | 1 |
| Song, WS | 1 |
| Cho, WH | 1 |
| Lee, SY | 1 |
| Jeon, DG | 1 |
| McCulloch, T | 1 |
| Prayle, A | 1 |
| Lunn, A | 1 |
| Watson, AR | 1 |
| Delaplace, M | 1 |
| Mélard, P | 1 |
| Perrinaud, A | 1 |
| Goré, C | 1 |
| Vergier, B | 1 |
| Machet, L | 1 |
| Yasuda, T | 1 |
| Suzuki, K | 1 |
| Kanamori, M | 1 |
| Hori, T | 1 |
| Huang, D | 1 |
| Bridge, JA | 1 |
| Kimura, T | 1 |
| Stephenson, J | 1 |
| Gow, KW | 1 |
| Meehan, J | 1 |
| Hawkins, DS | 2 |
| Avansino, J | 1 |
| Tural, D | 1 |
| Molinas Mandel, N | 1 |
| Dervisoglu, S | 1 |
| Oner Dincbas, F | 1 |
| Koca, S | 1 |
| Colpan Oksuz, D | 1 |
| Kantarci, F | 1 |
| Turna, H | 1 |
| Selcukbiricik, F | 1 |
| Hiz, M | 1 |
| Richey, SL | 1 |
| Rao, P | 1 |
| Wood, CG | 1 |
| Patel, S | 1 |
| Tannir, NM | 1 |
| Hall, KS | 1 |
| Eriksson, M | 1 |
| Ruggieri, P | 4 |
| Daolio, P | 1 |
| Lindholm, P | 1 |
| Grignani, G | 1 |
| Podda, M | 1 |
| Kuperman, AA | 1 |
| Kornreich, L | 1 |
| Feinmesser, M | 1 |
| Ash, S | 1 |
| Yaniv, I | 1 |
| Cohen, IJ | 1 |
| Hanly, L | 1 |
| Figueredo, R | 1 |
| Rieder, MJ | 1 |
| Koropatnick, J | 1 |
| Koren, G | 1 |
| Nieder, ML | 1 |
| Bernstein, ML | 2 |
| Henry, DW | 1 |
| Malkin, D | 1 |
| Baruchel, S | 1 |
| Chuba, PJ | 1 |
| Sailer, SL | 1 |
| Brown, K | 1 |
| Ernst, E | 1 |
| Kjærsgaard, M | 1 |
| Birkebæk, NH | 1 |
| Clausen, N | 1 |
| Andersen, CY | 1 |
| West, DC | 1 |
| Dickman, PS | 4 |
| Dormans, JP | 1 |
| Tanaka, K | 2 |
| Matsunobu, T | 1 |
| Sakamoto, A | 1 |
| Matsuda, S | 1 |
| Iwamoto, Y | 1 |
| Park, J | 1 |
| Kreissman, S | 1 |
| Thomson, B | 2 |
| Douglas, J | 1 |
| Rowley, SD | 1 |
| Gooley, T | 1 |
| Sanders, JE | 1 |
| Pendergrass, TW | 1 |
| Sancéau, J | 2 |
| Poupon, MF | 1 |
| Sastre-Garau, X | 1 |
| Wietzerbin, J | 2 |
| Tarbell, NJ | 3 |
| Link, MP | 3 |
| Fryer, CJ | 3 |
| Pritchard, DJ | 2 |
| Gebhardt, MC | 3 |
| Perlman, EJ | 3 |
| Donaldson, SS | 3 |
| Moore, S | 2 |
| Rausen, AR | 3 |
| Vietti, TJ | 3 |
| Miser, JS | 5 |
| Strauss, SJ | 1 |
| Driver, D | 1 |
| Hall-Craggs, M | 1 |
| Sandison, A | 1 |
| Cassoni, AM | 1 |
| Kilby, A | 1 |
| Michelagnoli, M | 1 |
| Pringle, J | 1 |
| Cobb, J | 1 |
| Briggs, T | 1 |
| Cannon, S | 2 |
| Witt, J | 1 |
| Whelan, JS | 1 |
| Kolb, EA | 1 |
| Kushner, BH | 3 |
| Laverdiere, C | 1 |
| LaQuaglia, MP | 2 |
| Huvos, AG | 1 |
| Qin, J | 1 |
| Vu, HT | 1 |
| Wexler, L | 1 |
| Wolden, S | 1 |
| Boehm, R | 1 |
| Till, H | 1 |
| Landes, J | 1 |
| Schmid, I | 1 |
| Joppich, I | 1 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| Kasper, B | 1 |
| Harter, C | 1 |
| Meissner, J | 1 |
| Bellos, F | 1 |
| Krasniqi, F | 1 |
| Ho, AD | 1 |
| Nakajima, W | 1 |
| Ishida, A | 1 |
| Washino, N | 1 |
| Ogawa, M | 1 |
| Takahashi, S | 1 |
| Okada, K | 1 |
| Müller, L | 1 |
| Kramm, CM | 1 |
| Lawrenz, W | 1 |
| Schmidt, KG | 1 |
| Wessalowski, R | 1 |
| Eroğlu, A | 1 |
| Kürkçüoğlu, IC | 1 |
| Karaoğlanoğlu, N | 1 |
| Alper, F | 1 |
| Gündoğdu, C | 1 |
| Goto, T | 2 |
| Kosaku, H | 1 |
| Kobayashi, H | 1 |
| Hozumi, T | 2 |
| Kondo, T | 2 |
| Krasin, MJ | 3 |
| Billups, CA | 4 |
| Davidoff, AM | 2 |
| Neel, MD | 2 |
| Merchant, TE | 3 |
| Kun, LE | 2 |
| Raja, M | 1 |
| Rahal, M | 1 |
| El Foudeh, M | 1 |
| Pai, C | 1 |
| El Hassan, I | 1 |
| Ezzat, A | 1 |
| Argon, A | 1 |
| Basaran, M | 1 |
| Yaman, F | 1 |
| Dizdar, Y | 1 |
| Sakar, B | 1 |
| Camlica, H | 1 |
| Bavbek, SE | 1 |
| Ozger, H | 1 |
| Darendeliler, E | 1 |
| Onat, H | 1 |
| Pierga, JY | 1 |
| Barthier, S | 1 |
| Babinet, A | 1 |
| Alapetite, C | 1 |
| Palangié, T | 1 |
| de Pinieux, G | 1 |
| Anract, P | 1 |
| Pouillart, P | 1 |
| Fuller, CE | 1 |
| La, TH | 1 |
| Alektiar, KM | 1 |
| Boland, PJ | 1 |
| Wolden, SL | 1 |
| Cozza, R | 1 |
| Ilari, I | 1 |
| De Sio, L | 1 |
| Boldrini, R | 1 |
| Jenkner, A | 1 |
| De Ioris, M | 1 |
| Inserra, A | 1 |
| Dominici, C | 1 |
| Donfrancesco, A | 1 |
| Navid, F | 2 |
| Santana, VM | 1 |
| Furman, WL | 1 |
| Spunt, SL | 2 |
| Cain, AM | 3 |
| Rao, BN | 3 |
| Hale, GA | 1 |
| Pappo, AS | 3 |
| Juergens, C | 1 |
| Weston, C | 1 |
| Ruiz Tovar, J | 1 |
| Reguero Callejas, ME | 1 |
| Arano Bermejo, JI | 1 |
| Capote Armas, LF | 1 |
| González-Palacios Martínez, F | 1 |
| Cabañas Navarro, L | 1 |
| Paulino, AC | 1 |
| Nguyen, TX | 1 |
| Mai, WY | 1 |
| Teh, BS | 1 |
| Wen, BC | 1 |
| Kołłataj, B | 1 |
| Zajaczkowska, M | 1 |
| Katski, K | 1 |
| Sikora, P | 1 |
| Pijanowska, M | 1 |
| Majewski, M | 1 |
| Kołłataj, W | 1 |
| Yock, TI | 1 |
| Chen, Z | 2 |
| Laurie, F | 1 |
| Bhatia, S | 1 |
| Burden, L | 1 |
| Askin, FB | 1 |
| Robison, LL | 1 |
| Naru, T | 1 |
| Nawaz, FH | 1 |
| Rizvi, J | 1 |
| Ozaki, T | 3 |
| Abe, S | 1 |
| Tsuchiya, H | 1 |
| Yabe, H | 1 |
| Al-Faris, N | 1 |
| Al Harbi, T | 1 |
| Goia, C | 1 |
| Pappo, A | 1 |
| Doyle, J | 1 |
| Gassas, A | 1 |
| Burke, MJ | 1 |
| Walterhouse, DO | 1 |
| Jacobsohn, DA | 1 |
| Duerst, RE | 1 |
| Kletzel, M | 1 |
| Smorenburg, CH | 1 |
| van Groeningen, CJ | 1 |
| Meijer, OW | 1 |
| Visser, M | 1 |
| Boven, E | 1 |
| Abla, O | 1 |
| Dror, Y | 1 |
| Shago, M | 1 |
| Liu, T | 1 |
| Okuma, T | 1 |
| Nakada, I | 1 |
| Arai, H | 1 |
| Rino, Y | 1 |
| Yamanaka, S | 2 |
| Yukawa, N | 1 |
| Wada, N | 1 |
| Kudo, M | 1 |
| Watanuki, Y | 1 |
| Fukumura, H | 1 |
| Nakajima, K | 1 |
| Oshiro, H | 1 |
| Masuda, M | 1 |
| Takeuchi, S | 1 |
| Akahoshi, Y | 1 |
| Kasai, C | 1 |
| Nishimoto, Y | 1 |
| Utracka-Hutka, B | 1 |
| Czownicki, Z | 1 |
| Schleicher, UM | 1 |
| Adam, G | 1 |
| Casser, HR | 1 |
| Füzesi, L | 1 |
| Gerald, WL | 1 |
| La Quaglia, MP | 1 |
| Boland, P | 1 |
| Wollner, N | 1 |
| Casper, ES | 1 |
| Aledo, A | 1 |
| Heller, G | 1 |
| Sauer, R | 2 |
| Pape, H | 1 |
| Rübe, C | 5 |
| Sugihara, S | 2 |
| Hamada, M | 2 |
| Nakagawa, Y | 2 |
| Inoue, H | 2 |
| Ashraf, MS | 1 |
| Brady, J | 1 |
| Breatnach, F | 1 |
| Deasy, PF | 1 |
| O'Meara, A | 1 |
| Hartley, JM | 3 |
| Hansen, L | 1 |
| Harland, SJ | 1 |
| Nicholson, PW | 2 |
| Pasini, F | 1 |
| Souhami, RL | 3 |
| Fabbri, N | 1 |
| Rosito, P | 6 |
| Ferraro, A | 1 |
| Casadei, R | 1 |
| Taguchi, K | 1 |
| Umeda, T | 2 |
| Kitoh, M | 2 |
| Tatezaki, S | 2 |
| Satoh, T | 2 |
| Sweeney, LE | 1 |
| Lowry, PA | 1 |
| Carstens, C | 1 |
| Iantorno, D | 2 |
| Forni, C | 4 |
| Campanacci, M | 1 |
| Voûte, PA | 3 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 1 |
| DeLaney, TF | 1 |
| Tsokos, M | 1 |
| Avila, N | 1 |
| Steinberg, SM | 1 |
| Weaver-McClure, L | 1 |
| Jacobson, J | 1 |
| Jarosinski, P | 1 |
| Hijazi, YM | 1 |
| Balis, FM | 1 |
| Horowitz, ME | 1 |
| Roguin, A | 1 |
| Ben Arush, MW | 1 |
| Higasi, A | 1 |
| Kuten, A | 1 |
| Cefalo, G | 1 |
| Tesoro-Tess, JD | 1 |
| Gianni, MC | 1 |
| Fossati-Bellani, F | 1 |
| Lombardi, F | 1 |
| Massimino, M | 1 |
| Verrill, MW | 1 |
| Judson, IR | 1 |
| Wiltshaw, E | 1 |
| Thomas, JM | 1 |
| Harmer, CL | 1 |
| Fisher, C | 1 |
| Singer, JM | 1 |
| Brennan, C | 1 |
| Antman, K | 1 |
| Crowley, J | 1 |
| Balcerzak, SP | 1 |
| Kempf, RA | 1 |
| Weiss, RB | 1 |
| Clamon, GH | 1 |
| Baker, LH | 1 |
| Ahrens, S | 6 |
| Cotterill, S | 1 |
| Malcolm, A | 1 |
| Souhami, R | 1 |
| Imeson, J | 1 |
| Hofmann, J | 1 |
| Hillmann, A | 1 |
| Mancini, A | 1 |
| Longhi, A | 3 |
| Rimondini, S | 2 |
| Di Liddo, M | 1 |
| Mancini, AF | 1 |
| Baldini, N | 1 |
| Hoffmann, C | 1 |
| Jabar, S | 1 |
| Braun-Munzinger, G | 1 |
| Heinecke, A | 1 |
| Göbel, U | 4 |
| Winkler, K | 2 |
| Ahmad, R | 1 |
| Mayol, BR | 1 |
| Davis, M | 1 |
| Rougraff, BT | 1 |
| Spanswick, VJ | 1 |
| Gander, M | 1 |
| Giacomini, G | 1 |
| Hartley, JA | 1 |
| Merimsky, O | 1 |
| Le Chevalier, T | 1 |
| Missenard, G | 1 |
| Lepechoux, C | 1 |
| Cojean-Zelek, I | 1 |
| Mesurolle, B | 1 |
| Le Cesne, A | 1 |
| Marina, NM | 2 |
| Parham, DM | 2 |
| Poquette, CA | 2 |
| Pratt, CB | 2 |
| Greenwald, C | 1 |
| Meyer, WH | 3 |
| Hawkins, D | 1 |
| Radich, J | 1 |
| Souid, AK | 1 |
| Fahey, RC | 1 |
| Dubowy, RL | 1 |
| Newton, GL | 1 |
| Bertoni, F | 1 |
| Bacchini, P | 1 |
| Manfrini, M | 1 |
| Donati, D | 1 |
| Shankar, AG | 1 |
| Pinkerton, CR | 1 |
| Atra, A | 1 |
| Ashley, S | 1 |
| Cotterill, SJ | 1 |
| Daller, RT | 1 |
| Fenton, JG | 1 |
| Elomaa, I | 1 |
| Blomqvist, CP | 1 |
| Saeter, G | 1 |
| Akerman, M | 1 |
| Stenwig, E | 1 |
| Björk, O | 1 |
| Kennedy, JG | 1 |
| Eustace, S | 1 |
| Caulfield, R | 1 |
| Fennelly, DJ | 1 |
| Hurson, B | 1 |
| O'Rourke, KS | 1 |
| McCarville, MB | 1 |
| Brandao, L | 1 |
| Exner, GU | 1 |
| Kotz, R | 1 |
| Amann, G | 1 |
| Dockhorn-Dworniczak, B | 1 |
| Müller-Weihrich, S | 1 |
| Welte, K | 1 |
| Kornhuber, B | 1 |
| Janka-Schaub, G | 1 |
| Sharon, N | 1 |
| Neumann, Y | 1 |
| Kenet, G | 1 |
| Schachter, J | 1 |
| Rechavi, G | 1 |
| Toren, A | 1 |
| Frisk, P | 1 |
| Stålberg, E | 1 |
| Strömberg, B | 1 |
| Cormier, JN | 1 |
| Herzog, CE | 1 |
| Ballo, MT | 1 |
| Burgess, MA | 1 |
| Feig, BW | 1 |
| Hunt, KK | 1 |
| Raney, RB | 1 |
| Zagars, GK | 1 |
| Pisters, PW | 1 |
| Lehnert, M | 1 |
| Taeger, D | 1 |
| Hense, HW | 1 |
| Wagner, A | 1 |
| Reiter, A | 1 |
| Henze, G | 1 |
| Niemeyer, C | 1 |
| Kremens, B | 1 |
| Fölsch, UR | 1 |
| Aulitzky, WE | 1 |
| Sokolov, T | 1 |
| Stoianova, A | 1 |
| Mumdjiev, I | 1 |
| Mihova, A | 1 |
| Könemann, S | 1 |
| Rübe, CE | 1 |
| Kun, L | 1 |
| Roberson, P | 1 |
| Parham, D | 1 |
| Rao, B | 1 |
| Fletcher, B | 1 |
| Zülfikar, B | 1 |
| Gedikoğlu, G | 1 |
| Antman, KH | 1 |
| Habrand, JL | 1 |
| Zucker, JM | 2 |
| Brunat-Mentigny, M | 2 |
| Terrier-Lacombe, MJ | 1 |
| Dubousset, J | 1 |
| Ponvert, D | 1 |
| Carrié, C | 1 |
| Ishida, S | 1 |
| Akiba, Y | 1 |
| Ohosaki, Y | 1 |
| Onodera, S | 1 |
| Fujita, Y | 1 |
| Tagaki, S | 1 |
| Shimizu, T | 1 |
| Sakai, E | 1 |
| Ikushima, Y | 1 |
| Saotome, K | 1 |
| Burgers, JM | 1 |
| Hawliczek, R | 1 |
| Kürten, R | 1 |
| Salzer-Kuntschik, M | 1 |
| Müschenich, M | 1 |
| Lemmi, MA | 1 |
| Fletcher, BD | 1 |
| Slade, W | 1 |
| Jenkins, JJ | 1 |
| Falkson, G | 1 |
| Chasen, MR | 1 |
| Falkson, HC | 1 |
| Dirix, LY | 2 |
| Van Oosterom, AT | 2 |
| Exner, U | 1 |
| Kühl, J | 1 |
| Ritter, J | 1 |
| Weinel, P | 1 |
| Deméocq, F | 1 |
| Benz-Lemoine, E | 1 |
| Boilletot, A | 1 |
| Behar, C | 1 |
| Poutard, P | 1 |
| Olive, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder[NCT06029465] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)[NCT00020566] | Phase 3 | 1,200 participants (Anticipated) | Interventional | 2001-02-28 | Recruiting | ||
| Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636] | Phase 3 | 907 participants (Actual) | Interventional | 2009-10-01 | Completed | ||
| Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment[NCT00824083] | 950 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool[NCT03968471] | 474 participants (Actual) | Observational | 2019-05-13 | Completed | |||
| EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92][NCT00002516] | Phase 3 | 0 participants | Interventional | 1992-07-31 | Active, not recruiting | ||
| A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031] | Phase 3 | 195 participants (Actual) | Interventional | 2009-07-01 | Completed | ||
| Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893] | 100 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors[NCT00061893] | Phase 2 | 38 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors[NCT00006734] | Phase 3 | 587 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898] | 414 participants (Actual) | Observational | 2004-03-12 | Completed | |||
| A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors[NCT00923351] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2007-06-02 | Completed | ||
| Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma[NCT00002466] | Phase 2 | 0 participants | Interventional | 1990-05-31 | Completed | ||
| INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY[NCT00002643] | Phase 2 | 130 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas[NCT00043979] | Phase 2 | 60 participants (Actual) | Interventional | 2002-09-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00061893)
Timeframe: 24 months after start of protocol therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Chemotherapy | 35 |
An incidence of severe toxicity is defined to be the occurrence of grade 3 or higher infection or grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy. If 12 or more patients experience grade 3 or higher infection or five or more patients experience grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy, the regimen will be flagged as being associated with an excessive rate of severe toxicity. (NCT00061893)
Timeframe: The first two cycles (6 weeks) of protocol chemotherapy
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 or Higher Infection | Grade 3 or Higher Sensory Neuropathy | |
| Combination Chemotherapy | 1 | 1 |
"A positive response to the tumor vaccine requires a positive reaction in at least one of the two assays below (immune responses to tumor lysates using ex vivo and delayed type of hypersensitivity (DTH).~The presence of a positive delayed type of hypersensitivity (DTH) reaction to the tumor lysate in a patient who did not show a positive DTH reaction prior to immunotherapy. A positive reaction is induration of at least 0.5 cm.~Immunotherapy administered to patients with recurrent or metastatic pediatric solid tumors such as Ewing's sarcoma, rhabdomyosarcoma, or neuroblastoma. Each vaccine is given as 6 separate injections. Three intradermal on one arm or leg and three subcutaneous on the other arm or leg." (NCT00923351)
Timeframe: Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (± 7 days) (Arm B)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 0 |
| Arm B - Participants Who Received rhIL-7 | 15 |
Overall survival is defined as the time between the first day of treatment to the day of death. (NCT00923351)
Timeframe: Time between the first day of treatment to the day of death or at the conclusion of 5 years of follow-up, whichever comes first, assessed up to approximately 11 years.
| Intervention | years (Median) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 2.4 |
| Arm B - Participants Who Received rhIL-7 | 4.3 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00923351)
Timeframe: Date treatment consent signed to date off study, approximately 49.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 6 |
| Arm B - Participants Who Received rhIL-7 | 24 |
The median CD4 count with a range of 85-1565 (absolute count) was used to determine recovery and were considered recovered if in this range. The CD4 count was established by flow cytometry testing. (NCT00043979)
Timeframe: Day +28-42
| Intervention | mm(3) (Median) |
|---|---|
| Arm 2-Recipients | 284 |
Participants who experienced recurrence or progression of disease following transplant. (NCT00043979)
Timeframe: up to 300 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 100 |
Progression free survival was based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months
| Intervention | Months (Median) |
|---|---|
| Arm 2-Recipients | 15.9 |
Days for participants to achieve a platelet count of 50,000/mm(3). (NCT00043979)
Timeframe: up to 43 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 15 |
Days for participants to achieve a neutrophil count of 500/mm(3). (NCT00043979)
Timeframe: up to 12 days
| Intervention | Days (Median) |
|---|---|
| Arm 2-Recipients | 9 |
GVT is defined as tumor response after day 42 post-transplantation without cytotoxic therapy. (NCT00043979)
Timeframe: up to day 100
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 2-Recipients | 0 |
Engraftment is defined as rapid conversion to complete donor chimerism and is assessed by blood counts and chimerism, >95% donor engraftment at day 100 in >75% of patients. (NCT00043979)
Timeframe: 100 days
| Intervention | Participants (Number) |
|---|---|
| Arm 2-Recipients | 23 |
Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00043979)
Timeframe: 16.5 months
| Intervention | Participants (Number) |
|---|---|
| Arm 2-Recipients | 30 |
Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2-D (dimensional) methods and registers four response categories: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is 30% increase in the sum of the longest diameter of target lesions. Progressive disease (PD) is 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria. For the purposes of this study very good partial response ((VGPR) is >75% reduction in disease) was also employed. (NCT00043979)
Timeframe: up to 10 cycles of therapy or 280 days
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response (CR) | Progressive Disease (PD) | Partial Response (PR) | Very Good Partial Response (VGPR) | |
| Arm 2-Recipients | 2 | 4 | 4 | 2 |
Median survival from date of progression is based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months
| Intervention | Months (Median) | |
|---|---|---|
| Participants who did not receive a transplant(n=7) | Participants who received a transplant (n=23) | |
| Arm 2-Recipients | 3.3 | 19.1 |
Participants who tolerated the transplantation regimen and accepted >95% of the donors blood, marrow, and/or tissue. (NCT00043979)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Day +14 | Day +28 | |
| Arm 2-Recipients | 23 | 23 |
Acute GVHD as by Modified Glucksberg Criteria occurring before day 100. Chronic GVHD as per Seattle criteria occurring after day 100. (NCT00043979)
Timeframe: up to 5 years or death
| Intervention | participants (Number) | |
|---|---|---|
| acute GVHD | chronic GVHD | |
| Recipients -Cyclosporine GVHD Prophylaxis | 12 | 12 |
| Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis | 5 | 5 |
Site of radiotherapy (high energy radiation) and/or toxicity experienced by the participants post HSCT radiotherapy. Grading was preformed using the Modified Glucksberg Criteria. (NCT00043979)
Timeframe: up to 6 cycles or 168 days
| Intervention | Participants (Count of Participants) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chest wall; G2 skin | Abdomen; G4 GI | Pancreas; G4 LFTs, G4 pancreatitis | Pleura, mediastinum; G4 LFTs, G2 mucositis | Chest wall; G4 skin, G3 mucositis | Spine, skull; G2 nausea+vomiting, G2 fatigue | Pelvis; G4 enteritis | Pulmonary (cyberknife) | Brain; B3 mucositis | Whole lung; G3 mucositis, G3 skin, G5 lung | L arm, R shoulder, B/L femur | |
| Arm 2-Recipients | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Participants who are alive at two years following Allo-Hematopoietic Stem Cell Transplant. (NCT00043979)
Timeframe: 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| From date of enrollment | From date of transplantation | |
| Arm 2-Recipients | 39.1 | 34.8 |
15 reviews available for ifosfamide and Ewing Sarcoma
| Article | Year |
|---|---|
Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2023 |
Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Cyclophosphamide; Dactinomycin; Etoposide; | 2019 |
Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2013 |
Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Etoposide; Fe | 2018 |
Extraskeletal Ewing's sarcoma of the thoracic epidural space: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epidural Neopl | 2011 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
Good outcome for infant of mother treated with chemotherapy for ewing sarcoma at 25 to 30 weeks' gestation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Gestational Age; Hu | 2004 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Extraskeletal Ewing's sarcoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy | 2000 |
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl | 2001 |
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo | 2001 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma, | 1990 |
The role of ifosfamide in the treatment of sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa | 1989 |
50 trials available for ifosfamide and Ewing Sarcoma
| Article | Year |
|---|---|
Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Humans | 2022 |
Radiation Therapy Dose Escalation in Unresectable Ewing Sarcoma: Final Results of a Phase 3 Randomized Controlled Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Fema | 2022 |
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactin | 2023 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Doxorubicin; Etoposide; Human | 2023 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; | 2020 |
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; | 2021 |
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2014 |
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Consolidation Chemotherapy; C | 2014 |
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; | 2015 |
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Carboplatin; Chi | 2015 |
Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, | 2015 |
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2009 |
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2009 |
Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Disease-Free Surviva | 2009 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Results of RS-99 protocol for childhood solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2010 |
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2010 |
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2010 |
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2010 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2011 |
Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2011 |
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chil | 2013 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2012 |
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2003 |
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2003 |
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2004 |
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil | 2006 |
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2006 |
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2006 |
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Ch | 2007 |
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a | 1981 |
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 1995 |
Salvage chemotherapy for recurrent Ewing's sarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1995 |
No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1993 |
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1996 |
Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1998 |
The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
Topics: Adult; Aged; Antineoplastic Agents; Biotransformation; Cross-Over Studies; Cyclophosphamide; Dexamet | 1998 |
A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1998 |
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1998 |
Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neo | 1999 |
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2000 |
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dactino | 1991 |
Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1989 |
123 other studies available for ifosfamide and Ewing Sarcoma
| Article | Year |
|---|---|
Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; COVID-19 Drug Treatment; Etoposide; Feasibili | 2022 |
Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2023 |
Analysis of stem cell collections in adult patients with Ewing sarcoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Child; Doxorubic | 2022 |
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; | 2023 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cholestasis; Cholestasis, Intrahepat | 2023 |
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2020 |
Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2019 |
Challenges in the management of localized Ewing sarcoma in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2020 |
[A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach].
Topics: Female; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Ifosfamide; In Situ Hybridization, F | 2020 |
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2021 |
Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 2021 |
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubici | 2017 |
Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Doxorubicin; Eto | 2017 |
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2017 |
Curettage, phenolization, and cementation in paediatric Ewing's sarcoma with a complete radiological response to neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Case- | 2019 |
Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cost-Benefit An | 2019 |
Multidisciplinary therapy including proton beam radiotherapy for a Ewing sarcoma family tumor of maxillary sinus in a 4-year-old girl.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality Therapy; Cycloph | 2013 |
Unusual case of recurrent extraneural metastatic medulloblastoma in a young adult: durable complete remission with Ewing sarcoma chemotherapy regimen and consolidation with autologous bone marrow transplantation and local radiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Cerebellar Neoplasms; Cycloph | 2013 |
Ifosfamide induced renal rickets.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child, Preschool; Chronic Kidney Disease-Mineral | 2014 |
Extraskeletal Ewing's Sarcoma: insight into a ten years follow-up.
Topics: Abdominal Neoplasms; Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2013 |
Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2014 |
Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2015 |
[VDC (A) + IE alternate chemotherapy].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Prognosis; Sarcoma, | 2015 |
Identification of Discrete Prognostic Groups in Ewing Sarcoma.
Topics: Adolescent; Adult; Age Factors; Bone Neoplasms; Child; Child, Preschool; Databases, Factual; Etoposi | 2016 |
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomyc | 2015 |
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin | 2016 |
Ewing Sarcoma: A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2016 |
Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi | 2016 |
Ewing sarcoma/primitive neuroectodermal tumor of the kidney treated with chemotherapy including ifosfamide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Kidney Neoplasms; Magneti | 2016 |
Maturation toward neuronal tissue in a Ewing sarcoma of bone after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calmodulin-Binding Proteins; Cell Differentiation; C | 2016 |
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cisplatin; Combined Modality The | 2017 |
Myeloablative chemotherapy with autologous stem cell rescue for Ewing sarcoma.
Topics: Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Myeloablative Agonists; Neoplasm Metastasi | 2008 |
Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality | 2009 |
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Ifosfamide; Male; Middle Aged; Neop | 2009 |
Extra-osseous Ewing sarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Ch | 2009 |
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil | 2009 |
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card | 2009 |
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy, | 2009 |
Primary intradural Ewing's sarcoma of the cauda equina presenting with acute bleeding.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cauda Equina; Decompression, S | 2010 |
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise | 2009 |
Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; | 2010 |
Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Doxorubicin; Etoposide; Humans; Ifosfamide; | 2010 |
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosph | 2010 |
Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactin | 2010 |
Chest wall Ewing sarcoma family of tumors: long-term outcomes.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2011 |
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor | 2010 |
Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleom | 2011 |
Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Biopsy; Cell Nucleus Shape; Chronic Disease; Disease | 2011 |
[Primitive cutaneous Ewing's sarcoma: a diagnostic and therapeutic dilemma].
Topics: 12E7 Antigen; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calmo | 2011 |
Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2012 |
Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Ifosfamid | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2012 |
Regression of mesenchymal hamartoma of the liver with sarcoma chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomyci | 2013 |
The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Growth Processes; C | 2012 |
Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cryopreservation; Cyclophosphamide; | 2013 |
High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2002 |
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2002 |
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 2002 |
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Etoposide; Fe | 2003 |
Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 2003 |
Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoprevention; Female; Huma | 2004 |
Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; H | 2004 |
Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Combined Modality The | 2004 |
Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2004 |
VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug R | 2004 |
Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 2004 |
Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide.
Topics: Angiogenesis Inducing Agents; Animals; Base Sequence; DNA Primers; Down-Regulation; Enzyme-Linked Im | 2004 |
Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modalit | 2005 |
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2006 |
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Clinical T | 2006 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo | 2006 |
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2007 |
[Acquired Fanconi-de Toni-Debre syndrome due to therapy for Ewing's sarcoma in 5-years old boy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child, Preschool; Dactinomycin; Doxo | 2006 |
Juvenile Ewing sarcoma presenting as a pelvic mass.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therap | 2007 |
Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi | 2007 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined | 2007 |
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2007 |
Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality | 2007 |
Translocation (X;10) in a child with therapy-related acute myeloid leukemia following chemotherapy for Ewing's Sarcoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma | 2007 |
Prognostic factors for local and distant control in Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Pres | 2008 |
[Preoperative adjuvant therapy for primary malignant bone tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo | 2007 |
[A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide].
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Lung Neoplasms; Male; Middle | 2008 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
[Extraosseous Ewing's sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Diag | 1995 |
Ifosfamide nephrotoxicity in paediatric cancer patients.
Topics: Adolescent; Child; Child, Preschool; Female; Glomerular Filtration Rate; Humans; Ifosfamide; Infant; | 1994 |
Metabolism of ifosfamide during a 3 day infusion.
Topics: Adenocarcinoma; Chromatography, Thin Layer; Female; Humans; Ifosfamide; Male; Neuroectodermal Tumors | 1994 |
Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1993 |
Ewing's sarcoma: evaluation of chemotherapy in 17 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinom | 1993 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Hypophosphataemic rickets after ifosfamide treatment in children.
Topics: Child; Fanconi Syndrome; Female; Humans; Ifosfamide; Knee Joint; Male; Phosphates; Radiography; Rick | 1993 |
Intense gallbladder uptake associated with chemotherapy. An unusual finding in pediatric skeletal scintigraphy.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; B | 1995 |
[Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 1995 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
[The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy, Adjuv | 1997 |
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch | 1997 |
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1997 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1998 |
Extraskeletal Ewing's sarcoma.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1999 |
Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.
Topics: Antineoplastic Agents, Alkylating; Cross-Linking Reagents; DNA Damage; Electrophoresis; Humans; Ifos | 1999 |
Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cesarean Section; Disease-Fre | 1999 |
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone N | 1999 |
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2000 |
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1999 |
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2000 |
Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2001 |
Successful pregnancy after high-dose cyclophosphamide and ifosfamide treatment in two postpubertal women.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Painful peripheral neuropathy after treatment with high-dose ifosfamide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Modality Therapy; Dose-Respo | 2001 |
[Treatment of Ewing's sarcoma with 2 different protocols].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
Postoperative radiotherapy in the treatment of Ewing tumors: influence of the interval between surgery and radiotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1992 |
Ewing's sarcoma: experience with 12 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1992 |
No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.
Topics: Bone Neoplasms; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Mal | 1992 |
[Two cases of Ewing's sarcoma originating from the adult rib].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 1991 |
Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1990 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 1990 |
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1989 |